Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world

被引：0
作者：
Ruixin Li
Ningling Wang
Xingxing Chai
Linhai Yang
Kangkang Liu
Hailong He
Shengyun Lin
Yan Yang
Jinsong Jia
Donghua Zhang
Yuemin Gong
Jinning Shi
Guangsheng He
Jianyong Li
机构：
[1] The First Affiliated Hospital of Nanjing Medical University,Department of Hematology
[2] Jiangsu Province Hospital,Department of Pediatrics
[3] The Second Hospital of Anhui Medical University,Department of Hematology
[4] The Second People’s Hospital of Lianyungang,Department of Hematology
[5] Children’s Hospital of Soochow University,Department of Hematology, Zhejiang Province Hospital of Traditional Chinese Medicine
[6] The First Affiliated Hospital of Zhejiang Chinese Medical University,Department of Hematology
[7] The First Bethune Hospital of Jilin University,Department of Hematology
[8] Peking University People’s Hospital,Department of Hematology
[9] Peking University Institute of Hematology,Department of Hematology
[10] Tongji Hospital,undefined
[11] Tongji Medical College,undefined
[12] Huazhong University of Science and Technology,undefined
[13] The Affiliated Jiangning Hospital of Nanjing Medical University,undefined
来源：
Clinical and Experimental Medicine | 2023年 / 23卷
关键词：
Severe aplastic anemia; Eltrombopag; Immunosuppressive therapy; Efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Eltrombopag (EPAG) can improve the efficacy of immunosuppressive therapy (IST) consisting of antithymocyte immunoglobulin (ATG) and cyclosporin in severe aplastic anemia (SAA) patients. This study explored whether patients with SAA could benefit from continuous usage of EPAG beyond 6 months.
引用
收藏
页码：2619 / 2627
页数：8
相关论文
共 91 条
[1]  
Young NS(2018)Aplastic anemia N Engl J Med 379 1643-1656
[2]  
Schoettler ML(2018)The pathophysiology of acquired aplastic anemia Hematol Oncol Clin N Am 32 581-594
[3]  
Nathan DG(2016)Guidelines for the diagnosis and management of adult aplastic anaemia Br J Haematol 172 187-207
[4]  
Killick SB(1995)Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia Blood 85 3058-3065
[5]  
Bown N(2018)First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: outcome of 955 patients treated 2001–2012 Am J Hematol 93 643-648
[6]  
Cavenagh J(2006)Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil Br J Haematol 133 606-611
[7]  
Rosenfeld SJ(2009)Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study Haematologica 94 348-354
[8]  
Kimball J(2000)Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia Blood 96 2049-2054
[9]  
Vining D(2019)Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ Blood 133 2043-2055
[10]  
Young NS(2009)Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist Stem Cells 27 424-430
12345678910